Companies › PleoPharma
1 active drug program in 1 registered trial: 1 Phase 3; Psychiatry; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PP-01 Cannabinoid-1 (CB1) partial agonist / GABAergic modulator | CNR1, GABA | Phase 3 | Cannabis Withdrawal | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07644052 | PP-01 | Phase 3 | Cannabis Withdrawal | Psychiatry | Jun 2027 |
Jazz Pharmaceuticals IGC Pharma Sinfatin Zynerba Pharmaceuticals Skye Bioscience Laboratorio Elea Phoenix Bazelet Nehushtan Incannex Healthcare Vertanical Alasht Pharmed
Bazelet Nehushtan Gedeon Richter Cybin IRL Beijing Union Pharmaceutical Factory Newron Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.